StockData

Keros Therapeutics vs Prothena Corp Public

KROS and PRTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KROS and PRTA compare

Prothena Corp Public is the larger company, worth 2.1 times as much as Keros Therapeutics ($409M against $199M).

Prothena Corp Public grew revenue faster over the last twelve months (427% versus −93.7% for Keros Therapeutics).

Prothena Corp Public keeps more of each dollar of sales as profit, with a net margin of −80.7% compared with −572% at Keros Therapeutics.

Prothena Corp Public scores higher on the StockData Score (12 against 7 for Keros Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKROSPRTA
Size and price
Market cap$199M$409M
Share price$10.03$7.97
Change, 1 year−42.0%−21.7%
Change, 5 years−82.1%−83.8%
Beta (5Y)2.220.93
Employees7867
StockData Score
Total score712 (better)
Valuation score13 (better)
Growth score01 (better)
Performance score12 (better)
Health score56 (better)
Dividend score00
Valuation
P/S13.7×7.5× (better)
P/B0.8× (better)1.4×
FCF yield−24.4%–
Fair value–$10.52
Margin of safety–24.3%
Growth
Revenue growth (TTM)−93.7%427% (better)
Revenue growth, 5Y average–62.6%
Net income growth (TTM)−543%–
EPS growth (TTM)−1287%–
Profitability
Operating margin−698%−102% (better)
Net margin−572%−80.7% (better)
FCF margin−334%–
Return on equity−17.2%−14.4% (better)
Return on invested capital−755%–
Financial health
Debt / equity0.000.00
Current ratio21.9625.05 (better)
Altman Z-score2.0710.17 (better)
Piotroski F-score6 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions101%92.2%
Held by insiders53.3%32.0%
Insider net buying, 12 months−$447K$13.1M (better)
Short interest, % of float11.7%22.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.